Parreño Caparrós Elena, Illán Gómez Fátima, Gonzálvez Ortega Manuel, Orea Soler Isabel, Pérez Paredes Matías, Lozano Almela Maria Luisa, Arjonilla Sampedro Elena, Alcaráz Tafalla Marisol
.
Nutr Hosp. 2017 Sep 14;34(5):1333-1337. doi: 10.20960/nh.1028.
Resistin was originally suggested to be a potential mediator of obesity-related insulin resistance in rodents. However, in humans, the role of resistin in obesity and insulin resistance has not yet been demonstrated. The present study investigates whether there are differences in resistin levels between patients with morbid obesity and lean subjects, and analyzes changes in resistin levels after significant weight loss secondary to bariatric surgery.
Sixty-eight patients with morbid obesity (body mass index [BMI] ≥ 40 kg/m2) and 31 lean subjects (BMI < 25 kg/m2) were selected. The study variables were: weight, height, BMI, waist-hip ratio (WHR), fat mass, family history of cardiovascular disease (CVD), type 2 diabetes mellitus (DM), hypertension, dyslipidemia, smoking, glucose, glycated hemoglobin (HbA1c), insulin, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), adiponectin and resistin. Homoeostasis model assessment (HOMA) and quantitative insulin sensitivity check index (QUICKI) were calculated. The obese patients underwent gastric bypass surgery, and the above mentioned variables were reassessed after 12 months and major weight loss.
There were no significant differences in resistin levels between morbidly obese patients and healthy subjects of normal weight, or between obese patients before and after weight loss. Resistin levels in morbidly obese patients were not correlated to adiposity anthropometric measures, insulin, glucose, HOMA, QUICKI, hsCRP, IL-6 or adiponectin. In the morbid obesity group, after one year of weight loss, the only study parameter correlated to resistin levels was IL-6.
Our results do not support a relationship among resistin levels, obesity and insulin resistance in humans.
抵抗素最初被认为是啮齿动物中肥胖相关胰岛素抵抗的潜在介质。然而，在人类中，抵抗素在肥胖和胰岛素抵抗中的作用尚未得到证实。本研究调查病态肥胖患者与瘦人之间抵抗素水平是否存在差异，并分析减肥手术后体重显著减轻后抵抗素水平的变化。
选取68例病态肥胖患者（体重指数[BMI]≥40kg/m²）和31例瘦人（BMI<25kg/m²）。研究变量包括：体重、身高、BMI、腰臀比（WHR）、脂肪量、心血管疾病（CVD）家族史、2型糖尿病（DM）、高血压、血脂异常、吸烟、血糖、糖化血红蛋白（HbA1c）、胰岛素、高敏C反应蛋白（hsCRP）、白细胞介素-6（IL-6）、脂联素和抵抗素。计算稳态模型评估（HOMA）和定量胰岛素敏感性检查指数（QUICKI）。肥胖患者接受胃旁路手术，12个月体重显著减轻后重新评估上述变量。
病态肥胖患者与正常体重健康受试者之间，或肥胖患者减肥前后的抵抗素水平均无显著差异。病态肥胖患者的抵抗素水平与肥胖人体测量指标、胰岛素、血糖、HOMA、QUICKI、hsCRP、IL-6或脂联素均无相关性。在病态肥胖组，减肥一年后，与抵抗素水平相关的唯一研究参数是IL-6。
我们的结果不支持人类抵抗素水平、肥胖和胰岛素抵抗之间存在关联。
